Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.

Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L.

J Urol. 2004 Jun;171(6 Pt 1):2250-4.

PMID:
15126796
[PubMed - indexed for MEDLINE]
2.

The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.

DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.

J Urol. 2005 Apr;173(4):1121-5.

PMID:
15758719
[PubMed - indexed for MEDLINE]
3.

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.

Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL.

Cancer. 2007 Jan 15;109(2):198-204.

PMID:
17171704
[PubMed - indexed for MEDLINE]
Free Article
4.

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB.

Urology. 2006 Feb;67(2):316-20. Epub 2006 Jan 25.

PMID:
16442597
[PubMed - indexed for MEDLINE]
5.

Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.

Candas B, Labrie F, Gomez JL, Cusan L, Chevrette E, Lévesque J, Brousseau G.

J Urol. 2006 Feb;175(2):510-6; discussion 516-7.

PMID:
16406983
[PubMed - indexed for MEDLINE]
6.

Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.

Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW.

J Endourol. 2007 Dec;21(12):1521-31. doi: 10.1089/end.2007.9875.

PMID:
18186694
[PubMed - indexed for MEDLINE]
7.

Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer.

Stone NN, Stock RG, Unger P.

J Urol. 2005 Mar;173(3):803-7.

PMID:
15711273
[PubMed - indexed for MEDLINE]
8.

Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.

Bangma CH, HOP WCJ, Schröder FH.

J Urol. 1995 Oct;154(4):1403-6.

PMID:
7544841
[PubMed - indexed for MEDLINE]
9.

Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.

Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL.

Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1302-8. doi: 10.1016/j.ijrobp.2007.11.073. Epub 2008 Feb 11.

PMID:
18262732
[PubMed - indexed for MEDLINE]
10.

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.

PMID:
15708249
[PubMed - indexed for MEDLINE]
11.

Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.

Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D.

Cancer. 2006 May 1;106(9):1875-82.

PMID:
16572409
[PubMed - indexed for MEDLINE]
Free Article
12.

Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.

Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC.

J Urol. 2004 Nov;172(5 Pt 1):1860-4.

PMID:
15540739
[PubMed - indexed for MEDLINE]
13.

Predictors of androgen independence in metastatic prostate cancer.

Sim HG, Lau WK, Cheng CW.

BJU Int. 2004 Jun;93(9):1221-4.

PMID:
15180610
[PubMed - indexed for MEDLINE]
14.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
[PubMed - indexed for MEDLINE]
15.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
[PubMed - indexed for MEDLINE]
16.

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.

Lee AK, Levy LB, Cheung R, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):456-62.

PMID:
15927415
[PubMed - indexed for MEDLINE]
17.

Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.

Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.

Cancer. 2005 Jan 15;103(2):242-50.

PMID:
15578715
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.

Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML.

J Urol. 2004 Dec;172(6 Pt 1):2244-8.

PMID:
15538240
[PubMed - indexed for MEDLINE]
20.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk